
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2015

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction
of incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02. Results of Operations and Financial Condition

On August 7, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended June 30, 2015. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated August 7, 2015, titled "Dynavax Reports Second Quarter 2015 Financial Results"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: August 7, 2015

By: /s/ DAVID JOHNSON
David Johnson
Vice President

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press Release, dated August 7, 2015, titled "Dynavax Reports Second Quarter 2015 Financial Results"

DYNAVAX

INNOVATING IMMUNOLOGY

2929 Seventh Street, Suite 100
Berkeley, CA 94710

Contact:

Michael Ostrach
Chief Financial Officer
510-665-7257
mostrach@dynavax.com

**DYNAVAX REPORTS SECOND QUARTER 2015
FINANCIAL RESULTS**

BERKELEY, CA – August 7, 2015 – Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2015.

The Company had \$93.4 million in cash, cash equivalents and marketable securities as of June 30, 2015, compared to \$97.6 million at March 31, 2015. The cash, cash equivalents and marketable securities balance as of June 30, 2015 includes net proceeds of approximately \$20.2 million as a result of stock sales under an at the market sales agreement (ATM). In July 2015, the Company received additional cash of approximately \$29 million resulting from stock sales under the ATM and also completed an underwritten public offering of common stock resulting in net proceeds of approximately \$135 million.

Operating expenses of \$24.8 million for the quarter ended June 30, 2015 decreased by \$2.3 million compared to the quarter ended March 31, 2015 as clinical costs associated with HBV-23, the ongoing Phase 3 clinical study of HEPLISAV-B™, Dynavax's investigational adult hepatitis B vaccine, began to decline as it progressed towards its expected completion in October 2015.

The net loss allocable to common stockholders for the quarter ended June 30, 2015 was \$23.6 million, or \$0.80 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended March 31, 2015 was \$26.2 million, or \$0.97 per basic and diluted share.

"With the completion of our recent financing we are well positioned to support the ongoing development of HEPLISAV-B and SD-101, our investigational cancer immunotherapeutic product, and to continue preparations for the anticipated commercial launch of HEPLISAV-B in the United States, subject to approval by the Food and Drug Administration," said Eddie Gray, Chief Executive Officer of Dynavax.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit www.dynavax.com.

Forward Looking Statements

This release contains forward-looking statements, including statements regarding our development and commercialization plans for our product candidates, including HEPLISAV-B and SD-101 and financial projections. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether HBV-23 can be completed as expected, whether the endpoints of the study will be achieved and the final results otherwise be satisfactory, whether successful development and approval of HEPLISAV-B and our process for its manufacture can occur in a timely manner or without significant additional studies or difficulties or delays; whether clinical studies for our products can be enrolled, supplied and completed in a timely manner and will be sufficient for further development or for marketing approval; the potential size and value of approved indications addressable with HEPLISAV-B and the commercial potential for HEPLISAV-B; initiation and completion of pre-clinical studies and clinical trials of our other product candidates; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; achieving the objectives of and maintaining our collaborative and licensing agreements; our ability to execute on our commercial strategies; whether our financial resources will be adequate without the need to obtain additional financing and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available.

– tables to follow –

DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2015	2014	2015	2014
Revenues:				
Collaboration revenue	\$ 930	\$ 2,031	\$ 1,401	\$ 4,404
Grant revenue	101	1,007	249	2,132
Service and license revenue	<u>519</u>	<u>10</u>	<u>527</u>	<u>10</u>
Total revenues	1,550	3,048	2,177	6,546
Operating expenses:				
Research and development	19,686	23,639	41,906	36,870
General and administrative	5,098	4,085	9,957	8,242
Unoccupied facility expense	-	<u>178</u>	-	<u>255</u>
Total operating expenses	<u>24,784</u>	<u>27,902</u>	<u>51,863</u>	<u>45,367</u>
Loss from operations	(23,234)	(24,854)	(49,686)	(38,821)
Interest income	18	55	45	120
Interest expense	(263)	-	(510)	-
Other (loss) income, net	<u>(112)</u>	<u>22</u>	<u>343</u>	<u>84</u>
Net loss	\$ <u>(23,591)</u>	\$ <u>(24,777)</u>	\$ <u>(49,808)</u>	\$ <u>(38,617)</u>
Basic and diluted net loss per share	\$ <u>(0.80)</u>	\$ <u>(0.94)</u>	\$ <u>(1.70)</u>	\$ <u>(1.47)</u>
Shares used to compute basic and diluted net loss per share	<u>29,335</u>	<u>26,286</u>	<u>29,230</u>	<u>26,286</u>

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)

	<u>June 30,</u> <u>2015</u>	<u>December 31,</u> <u>2014</u>
Assets		
Cash, cash equivalents and marketable securities	\$ 93,381	\$ 122,652
Property and equipment, net	8,887	7,924
Goodwill	2,078	2,277
Other assets	<u>5,148</u>	<u>5,437</u>
Total assets	\$ <u>109,494</u>	\$ <u>138,290</u>
Liabilities and stockholders' equity		
Deferred revenues	\$ 11,364	\$ 12,765
Other liabilities	15,641	15,484
Long-term debt	<u>7,961</u>	<u>9,559</u>
Total liabilities	34,966	37,808
Stockholders' equity	<u>74,528</u>	<u>100,482</u>
Total liabilities and stockholders' equity	\$ <u>109,494</u>	\$ <u>138,290</u>

#